NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$46.19
+0.11 (+0.24 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$45.89
$46.47
50-Day Range
$40.11
$46.66
52-Week Range
$34.18
$61.57
Volume655,157 shs
Average Volume836,083 shs
Market Capitalization$5.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.


NeoGenomics logo

About NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

452nd out of 1,309 stocks

Testing Laboratories Industry

1st out of 1 stocks

Analyst Opinion: 2.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view top-rated stocks.

What stocks does MarketBeat like better than NeoGenomics?

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for NeoGenomics
.

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Friday, August 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "42174".

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Wednesday, May, 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.05. The medical research company earned $115.30 million during the quarter, compared to the consensus estimate of $112.17 million. NeoGenomics had a negative net margin of 2.42% and a positive trailing twelve-month return on equity of 0.83%. NeoGenomics's revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) EPS.
View NeoGenomics' earnings history
.

How has NeoGenomics' stock been impacted by COVID-19?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 86.4% and is now trading at $46.19.
View which stocks have been most impacted by COVID-19
.

How often does NeoGenomics pay dividends? What is the dividend yield for NeoGenomics?

NeoGenomics declared a dividend on Tuesday, December 15th. Investors of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a dividend yield of 3.13%. The ex-dividend date of this dividend is Thursday, December 17th.
View NeoGenomics' dividend history
.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of -0.270--0.230 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.200. The company issued revenue guidance of $490 million-$510 million, compared to the consensus revenue estimate of $498.21 million.

What price target have analysts set for NEO?

10 brokers have issued 12-month target prices for NeoGenomics' shares. Their forecasts range from $14.50 to $65.00. On average, they anticipate NeoGenomics' share price to reach $52.05 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for NeoGenomics
or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mark Mallon, Chief Executive Officer & Director
  • George A. Cardoza, President & Chief Operating Officer-Lab Operations
  • Steven G. Brodie, VP-Worldwide Pharma Services Operations
  • Kathryn B. McKenzie, Chief Financial Officer
  • Steven A. Ross, Chief Information Officer & Vice President

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (0.85%), New York State Common Retirement Fund (0.84%), Granite Investment Partners LLC (0.79%), Emerald Advisers LLC (0.74%), Victory Capital Management Inc. (0.36%) and Redwood Investments LLC (0.30%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Oak Ridge Investments LLC, TCW Group Inc., Redwood Investments LLC, Oppenheimer Asset Management Inc., Rice Hall James & Associates LLC, and Handelsbanken Fonder AB. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Scout Investments Inc., MAI Capital Management, Alliancebernstein L.P., Exchange Traded Concepts LLC, GWM Advisors LLC, Advisor Group Holdings Inc., and Nkcfo LLC.
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $46.19.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $5.45 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600 or via email at [email protected]


This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.